GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultragenyx Pharmaceutical Inc (STU:UP0) » Definitions » Float Percentage Of Total Shares Outstanding

Ultragenyx Pharmaceutical (STU:UP0) Float Percentage Of Total Shares Outstanding : 85.76% (As of Jun. 06, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Ultragenyx Pharmaceutical Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Ultragenyx Pharmaceutical's float shares is 71.29 Mil. Ultragenyx Pharmaceutical's total shares outstanding is 83.13 Mil. Ultragenyx Pharmaceutical's float percentage of total shares outstanding is 85.76%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Ultragenyx Pharmaceutical's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Ultragenyx Pharmaceutical's Institutional Ownership is 57.89%.


Ultragenyx Pharmaceutical Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Ultragenyx Pharmaceutical's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=71.29/83.13
=85.76%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ultragenyx Pharmaceutical (STU:UP0) Business Description

Industry
Traded in Other Exchanges
Address
60 Leveroni Court, Novato, CA, USA, 94949
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Ultragenyx Pharmaceutical (STU:UP0) Headlines

No Headlines